Evidence map›Paper›PMID 35733875›Full record

ArticleFrontiers in medicine2022

Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis.

Xianglin Zhou, Danhui Yang, Xianglong Kong, Chengli Wei, Siqi LvQiu, Lin Wang, Yongkang Lin, Zhilan Yin, Zhiguo Zhou, Hong Luo

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. The Hidden Pandemic of COVID-19-Induced Organizing Pneumonia.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  16. Review
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Xianglin ZhouDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.
Danhui YangDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.
Xianglong KongRespiratory Medicine, The First Hospital of Changsha, Changsha, China.
Chengli WeiDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.
Siqi LvQiuDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.
Lin WangDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.
Yongkang LinDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.
Zhilan YinDepartment of Radiology, The Second Xiangya Hospital, Central South University, Changsha, China.
Zhiguo ZhouRespiratory Medicine, The First Hospital of Changsha, Changsha, China.
Hong LuoDepartment of Pulmonary and Critical Care Medicine, the Second Xiangya Hospital, Central South University, Changsha, China.
Hunan Provincial Center for Disease Control and Prevention · CNCentral South University · CNThe First Hospital of Changsha · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pulmonary fibrosis is one of the sequelae of the COVID-19, which seriously affects the quality of life of survivors. Currently, there are no optimal evidence based guidelines targeting this population. Case Presentation: We report a 66-year-old female patient without underlying comorbidities admitted to Changsha Public Health Center because of COVID-19. During hospitalization, she developed co-bacterial infection and acute respiratory distress syndrome, and received broad-spectrum antibacterial therapy, invasive mechanical ventilation and extracorporeal membrane oxygenation. After the acute phase, she developed post-COVID-19 pulmonary fibrosis subsequently treated with pirfenidone. Over 96 weeks after pirfenidone treatment, her modified Medical Research Council Dyspnea level improved to 2 from 4 at discharge. Her 6 minutes walk test distance, total lung capacity, and diffusion capacity for carbon monoxide all increased. Chest CT performed on 2 years after illness onset showed regressing fibrosis. The Hospital Anxiety and Depression Scale, Athens Insomnia Scale, and 36-Item Short Form Health Survey questionnaire all improved. Conclusion: Post-COVID-19 pulmonary fibrosis is a challenging consequence of COVID-19, and our case suggests that pirfenidone may be an effective treatment option.

Indexed as

long COVIDpirfenidonepost-COVID-19pulmonary fibrosissequelae

Identifiers

PMID35733875
PMCPMC9207265
OpenAlexW4281665748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.